The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Open accessAbstract
BACKGROUND: The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. DESIGN: Treatments were assessed in light of their intensity, duration and side-effects, estimating the magnitude of clinical benefit according to stage and biology of the disease. The Panel acknowledged that for many patients, the impact of adjuvant therapy or the adherence to specific guidelines may have modest impact on the risk of breast cancer recurrence or overall survival. For that reason, the Panel explicitly encouraged clinicians and patients to routinely discuss the magnitude of benefit for interventions as part of the development of the treatment plan. RESULTS: The guidelines focus on common ductal and lobular breast cancer histologies arising in generally healthy women. Special breast cancer histologies may need different considerations, as do individual patients with other substantial health considerations. The panelists' opinions reflect different interpretation of available data and expert opinion where is lack of evidence and sociocultural factors in their environment such as availability of and access to medical service, economic resources and reimbursement issues. Panelists encourage patient participation in well-designed clinical studies whenever available. CONCLUSIONS: With these caveats in mind, the St. Gallen Consensus Conference seeks to provide guidance to clinicians on appropriate treatments for early-stage breast cancer and guidance for weighing the realistic tradeoffs between treatment and toxicity so that patients and clinical teams can make well-informed decisions on the basis of an honest reckoning of the magnitude of clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · cited 1×
“Late stage, TNBC: clinical The Impassion130 trial showed that adding the anti-PD-L1 antibody, atezolizumab to nab-paclitaxel improves PFS, and may improve OS, in women with TNBC that are PD-L1 ICþ on biomarker testing [23]”
BackgroundSelf-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationAdjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397 · cited 4×
“The prospective, randomized TAILORx trial demonstrates that there is no clinical benefit for adding chemotherapy to endocrine therapy in the treatment of women with node-negative, T1/T2 tumors and 21-gene recurrence scores of 11 to 25 [27] Early Stage ER-positive breast cancer: clinical”
BackgroundInfluentialTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157 · cited 1×
“Biomarkers Tumor-infiltrating lymphocytes (TILs) were established as a favorable prognostic marker in TNBC patients received adjuvant/neoadjuvant chemotherapy [35, 36]”
BackgroundSelf-citation70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., et al. (2017) · JAMA · doi:10.1001/jama.2017.11470 · Cited by 1,912
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Whelan, T. J., Pignol, J.-P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., Shelley, W., Grimard, L., Bowen, J., Lukka, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906260 · Cited by 1,878
Donker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J. H., Mansel, R. E., Cataliotti, L., Westenberg, A. H., Klinkenbijl, J. H. G., Orzalesi, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70460-7 · Cited by 1,871
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Boughey, J. C. (2013) · JAMA · doi:10.1001/jama.2013.278932 · Cited by 1,588
Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., Lebeau, A., Liedtke, C., Minckwitz, G. V., Nekljudova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70166-9 · Cited by 1,485
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., Muss, H. B., Smith, B. L., Hudis, C. A., Winer, E. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2615 · Cited by 1,310
Self-citationRegional Nodal Irradiation in Early-Stage Breast Cancer
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., Vallis, K. A., White, J. R., Rousseau, P., Fortin, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415340 · Cited by 1,294
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276 · cited 1×
“Maturing data from multiple trials of CDK 4/6 inhibitors – palbociclib, ribociclib, abemaciclib – show durable improvements in PFS when combined with endocrine therapy in 1st or 2nd line treatment of ER-positive advanced breast cancer, and show emerging survival benefit [56-59] Advanced Stage ER-positive breast cancer…”
Self-citationSchneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Self-citationAsselain, B., Barlow, W., Bartlett, J., Bergh, J., Bergsten-Nordström, E., Bliss, J., Boccardo, F., Boddington, C., Bogaerts, J., Bonadonna, G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30777-5 · Cited by 1,118
Self-citationTripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025 · cited 1×
“Maturing data from multiple trials of CDK 4/6 inhibitors – palbociclib, ribociclib, abemaciclib – show durable improvements in PFS when combined with endocrine therapy in 1st or 2nd line treatment of ER-positive advanced breast cancer, and show emerging survival benefit [56-59] Advanced Stage ER-positive breast cancer…”
Self-citationSikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Self-citationKunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A., & Dixon, J. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71221-5 · Cited by 904
Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893 · cited 1×
“Biomarkers Tumor-infiltrating lymphocytes (TILs) were established as a favorable prognostic marker in TNBC patients received adjuvant/neoadjuvant chemotherapy [35, 36]”
BackgroundSelf-citationGianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874 · cited 15×
“Chemotherapy for triple-negative breast cancers Chemotherapy is the mainstay of neo/adjuvant treatment of TNBC. Based on a recent meta-analysis [26], the Panel endorsed ‘dose-dense’ treatment as the preferred approach for anthracycline- and taxane-based neo/adjuvant chemotherapy regimens.”
BackgroundInfluentialLoibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Self-citationTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 684
Self-citationStrnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., Lyczek, J., Guinot, J. L., Dunst, J., Miguelez, C. G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00471-7 · Cited by 659
Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Solky, A. J., Stearns, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01160 · Cited by 636
Self-citationMartin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S. K. L., Mansi, J., Barrios, C. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30717-9 · Cited by 585
Self-citationHammond, M. E. H., Hayes, D. F., Wolff, A. C., Mangu, P. B., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.777003 · Cited by 583
Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy
Moore, H. C. F., Unger, J. M., Phillips, K.-A., Boyle, F., Hitre, E., Porter, D., Francis, P. A., Goldstein, L. J., Gomez, H. L., Vallejos, C. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413204 · Cited by 553
Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., Jerusalem, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30812-x · Cited by 470
Self-citationLivi, L., Meattini, I., Marrazzo, L., Simontacchi, G., Pallotta, S., Saieva, C., Paiar, F., Scotti, V., De Luca Cardillo, C., Bastiani, P., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.013 · Cited by 460
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3935 · Cited by 451
O’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 414
Cm, R., Zahrieh, D., Forbes, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5784 · Cited by 408
Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 400
Self-citationMcCormick, B., Winter, K., Hudis, C., Kuerer, H. M., Rakovitch, E., Smith, B. L., Sneige, N., Moughan, J., Shah, A., Germain, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9029 · Cited by 392
Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., & Katz, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01854 · Cited by 387 · cited 1×
“Algorithms for genetic testing that seek to identify patients with higher risk of harboring a deleterious mutation may nonetheless miss larger numbers of patients with such mutations [41]”
BackgroundDel Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S., Giordano, M., Garrone, O., Pronzato, P., Bighin, C., et al. (2011) · JAMA · doi:10.1001/jama.2011.991 · Cited by 351
Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y., Kerbrat, P., Bachelot, T., Lortholary, A., Espié, M., Fumoleau, P., Serin, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70225-0 · Cited by 337
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Self-citationHershman, D. L., Unger, J. M., Greenlee, H., Capodice, J. L., Lew, D. L., Darke, A. K., Kengla, A. T., Melnik, M. K., Jorgensen, C. W., Kreisle, W. H., et al. (2018) · JAMA · doi:10.1001/jama.2018.8907 · Cited by 300
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy460 · Cited by 295
Self-citationBlum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O'Shaughnessy, J. A., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294
Weigelt, B., Comino-Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C., Cutts, R., Martelotto, L. G., Ng, C. K. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0544 · Cited by 263
Burstein, H. J., Lacchetti, C., & Griggs, J. J. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00617 · Cited by 248
Self-citationGnant, M., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balic, M., Haslbauer, F., Melbinger-Zeinitzer, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30862-3 · Cited by 239
Self-citationNangia, J., Wang, T., Osborne, C., Niravath, P., Otte, K., Papish, S., Holmes, F., Abraham, J., Lacouture, M., Courtright, J., et al. (2017) · JAMA · doi:10.1001/jama.2016.20939 · Cited by 233
Nanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero-Torres, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204
Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., Maartense, E., van Leeuwen-Stok, A. E., Liefers, G.-J., Nortier, J. W. R., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 200
Simons, J. M., van Nijnatten, T. J. A., van der Pol, C. C., Luiten, E. J. T., Koppert, L. B., & Smidt, M. L. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003075 · Cited by 196
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
Rugo, H. S., Klein, P., Melin, S. A., Hurvitz, S. A., Melisko, M. E., Moore, A., Park, G., Mitchel, J., Bågeman, E., D’Agostino, R. B., et al. (2017) · JAMA · doi:10.1001/jama.2016.21038 · Cited by 190
Nitz, U., Gluz, O., Christgen, M., Kates, R. E., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4358-6 · Cited by 189
Metzger Filho, O., Giobbie-Hurder, A., Mallon, E., Gusterson, B., Viale, G., Winer, E. P., Thürlimann, B., Gelber, R. D., Colleoni, M., Ejlertsen, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8133 · Cited by 188
Self-citationLænkholm, A.-V., Jensen, M.-B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., Ferree, S., Schaper, C., Nielsen, T. O., Haffner, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6586 · Cited by 176
Fribbens, C., Garcia Murillas, I., Beaney, M., Hrebien, S., O’Leary, B., Kilburn, L., Howarth, K., Epstein, M., Green, E., Rosenfeld, N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx483 · Cited by 168
Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J.-H., Geyer, C. E., Rastogi, P., Fehrenbacher, L., Graham, M. L., Chia, S. K., Brufsky, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30621-1 · Cited by 167
Melisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155 · cited 1×
“Vaginal estrogen or testosterone therapy reduced symptoms of AI-associated vaginal dryness or loss of libido without causing increases in serum estradiol levels [55]”
BackgroundJoensuu, H., Fraser, J., Wildiers, H. P. M. W., Huovinen, R., Auvinen, P., Utriainen, M., Nyandoto, P., Villman, K., Halonen, P., Björneklett, H. G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1380 · Cited by 152
Nitz, U. A., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Pollmanns, A., Lorenz-Salehi, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00028 · Cited by 144
Henry, N. L., Unger, J. M., Schott, A. F., Fehrenbacher, L., Flynn, P. J., Prow, D. M., Sharer, C., Burton, G. V., Kuzma, C. S., Moseley, A. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6651 · Cited by 128
Dungan, J. S. (2012) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2012.06.157 · Cited by 124
Ruhstaller, T., Giobbie‐Hurder, A., Colleoni, M. A., Jensen, M., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E. H., Gladieff, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00440 · Cited by 111
Self-citationFunctional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
Lei, J. T., Shao, J., Zhang, J., Iglesia, M. D., Chan, D. W., Cao, J., Anurag, M., Singh, P., He, X., Kosaka, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.009 · Cited by 109
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W. J., Masuda, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1002 · Cited by 99
Dieci, M. V., Conte, P., Bisagni, G., Brandes, A. A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz007 · Cited by 95
Pilewskie, M. L., Stempel, M. M., Rosenfeld, H., Eaton, A. A., Zee, K. J. V., & Morrow, M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5268-2 · Cited by 74
Loibl, S., Untch, M., Burchardi, N., Huober, J., Blohmer, J., Grischke, E., Furlanetto, J., Tesch, H., Hanusch, C. A., Rezai, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.104 · Cited by 70
Self-citationEarl, H., Hiller, L., Vallier, A.-L., Loi, S., Howe, D., Higgins, H. B., McAdam, K., Hughes‐Davies, L., Harnett, A., Ah-See, M.-L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.506 · Cited by 69
Ejlertsen, B., Tuxen, M. K., Jakobsen, E. H., Jensen, M., Knoop, A. S., Højris, I., Ewertz, M., Balslev, E., Danø, H., Vestlev, P. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.3494 · Cited by 67
Juric, D., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H., Iwata, H., Conte, P., Mayer, I., Kaufman, B., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-gs3-08 · Cited by 62
Self-citationLitton, J. K., Scoggins, M. E., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0052-4 · Cited by 59
Janni, W., Rack, B. K., Friedl, T. P., Müller, V., Lorenz, R., Rezai, M., Tesch, H., Heinrich, G., Andergassen, U., Harbeck, N., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-gs5-03 · Cited by 29
Gregg, J. R., Reichard, C. A., Wang, X., Chapin, B. F., Pisters, L. L., Pettaway, C. A., Ward, J. F., Achim, M. F., Choi, S. L., Kuban, D. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.104 · Cited by 15
Cited by
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Self-citationLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Self-citationMittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Metadata
- Authors
- Burstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., Piccart-Gebhart, M., Regan, M., Senn, H.-J., Winer, E. P., & Thurlimann, B.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Issue
- 10
- Pages
- 1541-1557
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2965857754
- Cited by
- 667
- References
- 83
- FWCI
- 27.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.